Mehkri S, Dinesh K G, Ashok G, Bopanna Krathish
Research and Development, Bio-gen Extracts Pvt Ltd., Bengaluru, Karnataka, India.
Research and Development Radiant Research Pvt Ltd., Bengaluru, Karnataka, India.
Indian J Pharmacol. 2025 Jul 1;57(4):219-225. doi: 10.4103/ijp.ijp_964_24. Epub 2025 Jul 21.
Palmitoylethanolamide (PEA) is an endogenous fatty acid amide signaling molecule that may indirectly modulate the endocannabinoid system. It has poor water solubility and, therefore, is not readily absorbed in the human body. Various formulation techniques have been developed to enhance the rate of dissolution of PEA and minimize the variability of drug absorption when administered orally. The present study compared the pharmacokinetics (PKs) of two different grades of micronized PEA, a water-dispersible PEA, and standard PEA in male Sprague-Dawley rats, following a single oral administration.
The drug PKs of each form of PEA-micronized (PEA-10µm), micronized PEA 6 µm (PEA-6 µm), and water-dispersible PEA (PEA-WD), were assessed and compared against a standard nonmicronized PEA (PEA-nm) using male Sprague-Dawley rats after a single dose oral administration. PEA plasma concentration (ng/mL) across all groups was determined using the liquid chromatography with tandem mass spectrometry method.
PEA supplementation significantly increased the total area under curve (AUC) in all the groups compared to PEA-nm, with PEA-WD (P < 0.001) exhibiting an exceptionally large effect of > 16 times. In addition, the PEA supplementation raised the maximum concentration (Cmax) from the baseline in all the groups. When Cmax for each group was compared against PEA-nm at a probability level of 0.05, PEA-10 µm indicated no statistically significant difference (P = 0.060), whereas PEA-6 µm (P < 0.001) and PEA-WD (P < 0.001) displayed a statistically significant difference at the aforesaid probability level.
PEA-WD demonstrated a higher total AUC and Cmax, followed by PEA-6 µm and PEA-10 µm compared to nonmicronized form of PEA. This indicates greater bioavailability of water-dispersible PEA, thus making it a promising candidate for enhancing clinical outcomes.
棕榈酰乙醇胺(PEA)是一种内源性脂肪酸酰胺信号分子,可能间接调节内源性大麻素系统。它的水溶性较差,因此在人体中不易被吸收。已开发出各种制剂技术来提高PEA的溶解速率,并在口服给药时使药物吸收的变异性最小化。本研究比较了两种不同等级的微粉化PEA、一种水分散性PEA和标准PEA在雄性Sprague-Dawley大鼠单次口服给药后的药代动力学(PKs)。
使用雄性Sprague-Dawley大鼠,在单次口服给药后,评估并比较每种形式的PEA(微粉化PEA-10µm、微粉化PEA 6µm(PEA-6µm)和水分散性PEA(PEA-WD))的药物PKs,并与标准非微粉化PEA(PEA-nm)进行比较。使用液相色谱-串联质谱法测定所有组的PEA血浆浓度(ng/mL)。
与PEA-nm相比,补充PEA显著增加了所有组的曲线下总面积(AUC),其中PEA-WD(P < 0.001)表现出超过16倍的异常大的效应。此外,补充PEA提高了所有组相对于基线的最大浓度(Cmax)。当在0.05的概率水平下将每组的Cmax与PEA-nm进行比较时,PEA-10µm无统计学显著差异(P = 0.060),而PEA-6µm(P < 0.001)和PEA-WD(P < 0.001)在上述概率水平下显示出统计学显著差异。
与非微粉化形式的PEA相比,PEA-WD表现出更高的总AUC和Cmax,其次是PEA-6µm和PEA-10µm。这表明水分散性PEA具有更高的生物利用度,因此使其成为改善临床结果的有前景的候选药物。